Xiaolin Li, 37South San Francisco, CA

8535726, Sep 17, 2013

Jul 24, 2008

12/178891

Hongjie Dai - Cupertino CA, US
Zhuang Liu - Stanford CA, US
Xiaolin Li - Menlo Park CA, US
Xiaoming Sun - Palo Alto CA, US

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

A61K 9/16
A61K 9/50

424490, 977742

Disclosed are nanoparticles, such as carbon nanotubes or other graphitic sheet materials having extended aromatic surfaces, which are used to deliver active agents such as drugs, labels or dyes (termed for convenience a “drug”) to the interior of cells. The nanoparticles are functionalized by a hydrophilic polymer or adsorption of an amphiphilic molecule to render them stable in suspension. The drug is therefore capable of release in the cell exterior. The drug is more rapidly released at lower pH, as found e. g. , in tumor cells. The drug may also be linked to a branched chain hydrophilic polymer, so that each polymer molecule carries more than one drug bound by a cleavable linker.

2010002, Feb 4, 2010

Jul 24, 2009

12/508754

Hongjie Dai - Cupertino CA, US
Xiaolin Li - Menlo Park CA, US
Xiaoming Sun - Beijing, CN

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

B32B 9/04
C09K 11/06

428408, 25230116, 562408, 528361

Disclosed are dispersed graphene sheets, ribbons, graphene molecules and the like which are pristine in the plane, i.e., free of significant defects and chemical modifications such as oxidation. The materials could be functionalized at the edges. These materials are dispersed in solutions rather than in aggregated or insoluble forms as their parent starting materials. Also disclosed is a method comprising the steps of intercalating an insoluble graphitic material. The method may comprise exfoliating graphite and re-intercalating the resultant material with an acid composition, such as oleum, and a strong organic base such as tetrabutylammonium hydroxide in a solvent solution to form a homogenous suspension, which is then agitated to form dispersed graphene materials. The materials may be solubilized with a hydrophilic polymer and can be further manipulated by transfer into different solvents, formation of films, application to optical and electronic devices, and other applications. The materials are solubilized by functional groups mostly at the edges.

2014001, Jan 16, 2014

Sep 16, 2013

14/028353

Zhuang Liu - Stanford CA, US
Xiaolin Li - Menlo Park CA, US
Xiaoming Sun - Palo Alto CA, US

The Board of Trustees of the Leland Stanford Junior University - Palo Alto CA

A61K 47/48
A61K 31/337
A61K 31/704
A61K 39/395
A61K 38/16

424490, 424400, 4241781, 514 211, 514 34, 514449, 514785, 514788, 530300, 5303917, 536 64, 549510, 428402

Disclosed are nanoparticles, such as carbon nanotubes or other graphitic sheet materials having extended aromatic surfaces, which are used to deliver active agents such as drugs, labels or dyes (termed for convenience a “drug”) to the interior of cells. The nanoparticles are functionalized by a hydrophilic polymer or adsorption of an amphiphilic molecule to render them stable in suspension. The drug is therefore capable of release in the cell exterior. The drug is more rapidly released at lower pH, as found e.g., in tumor cells. The drug may also be linked to a branched chain hydrophilic polymer, so that each polymer molecule carries more than one drug bound by a cleavable linker.

2023005, Feb 16, 2023

Jun 21, 2021

17/352734

- Basel, CH
Xiaolin Li - Alameda CA, US
Peichao Lu - Pleasant Hill CA, US
Naomi Samadara Rajapaksa - Fremont CA, US
David Charles Tully - Danville CA, US
Xiaojing Michael Wang - Livermore CA, US
Qian Zhao - Louisville CO, US

C07D 471/04
A61P 31/22

The invention provides compounds of Formula (I)as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

2020016, May 21, 2020

Nov 18, 2019

16/686889

- Cupertino CA, US
Richard M. Mank - Cupertino CA, US
Hyea Kim - Campbell CA, US
Hongli Dai - Los Altos CA, US
Sunho Kang - San Jose CA, US
Ji-Guang Zhang - Richland WA, US
Ran Yi - Richland WA, US
Qiuyan Li - Richland WA, US
Xiaolin Li - Richland WA, US
Wu Xu - Richland WA, US
Rajankumar L. Patel - Richland WA, US
Hyung-Seok Lim - Richland WA, US
Chongmin Wang - Richland WA, US
Langli Luo - Richland WA, US
Yang He - Richland WA, US

H01M 4/134
H01M 4/133
H01M 10/0525

An anode active material comprises a silicon-carbon secondary particle comprising a composite having an exterior conformal carbon coating and formed of type I primary particles. Each type I primary particle comprises a core particle of interconnected silicon, the interconnected silicon formed of nano-sized silicon particles each connected to at least one other particle, inner pores internal to the core particle and defined by the interconnected silicon, an internal carbon coating on internal wall surfaces of the inner pores and a conformal carbon coating on the core particle.

2020007, Mar 12, 2020

Sep 12, 2019

16/569107

- Basel, CH
Xiaolin Li - Alameda CA, US
Peichao Lu - Pleasant Hill CA, US
Naomi Samadara Rajapaksa - Fremont CA, US
David Charles Tully - Danville CA, US
Xiaojing Michael Wang - Livermore CA, US
Qian Zhao - Louisville CO, US

C07D 471/04
A61P 31/22

The invention provides compounds of Formula (I)as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by herpesviruses.

2017021, Aug 3, 2017

Aug 3, 2015

15/500870

Zhigan JIANG - Shanghai, CN
Jianhua XIA - Shanghai, CN
Haiying HE - Shanghai, CN
- Basel, CH
Xiaolin LI - Alameda CA, US
Peichao LU - Pleasant Hill CA, US
Wosenu MERGO - Oakland CA, US
Daniel MUTNICK - Concord CA, US
Folkert RECK - Walnut Creek CA, US
Alexey RIVKIN - Emeryville CA, US
Colin Keith SKEPPER - Alameda CA, US
Xiaojing Michael WANG - Livermore CA, US
Yongjin XU - Castro Valley CA, US

C07D 215/38
A61K 31/4709
A61K 31/496
C07D 401/14
C07D 413/14
C07D 419/14
C07D 405/14
C07D 471/04
C07D 498/10
A61K 31/5377
A61K 31/5386
C07D 487/10
C07D 471/10
A61K 45/06
C07D 401/04

This invention is in the field of medicinal chemistry and relates to compounds, and pharmaceutical compositions thereof, that inhibit bacterial gyrase. The compounds are useful as inhibitors of bacterial gyrase activity and bacterial infections, and have the structure of Formula (I)as further described herein. The invention further provides pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds and compositions to treat bacterial infections.

2015030, Oct 29, 2015

May 20, 2015

14/717872

Jiping Fu - Danville CA, US
Subramanian Karur - Dublin CA, US
Xiaolin Li - Alameda CA, US
Peichao Lu - Pleasant Hill CA, US
Wosenu Mergo - Oakland CA, US
Alexey Rivkin - Emeryville CA, US
Zachary Kevin Sweeney - Redwood City CA, US
Meiliana Tjandra - Dublin CA, US
Andrew Weiss - San Francisco CA, US
Aregahegn Yifru - Pleasant Hill CA, US

NOVARTIS AG - Basel

A61K 38/13
A61K 45/06
C07K 7/64

The present invention provides a compound of formula I;or a pharmaceutically acceptable salt thereof, wherein R, R, R, R, R, and A-B are as defined herein, which are non-immunosuppressive, cyclophilin-binding, mPTP blockers and are therefore useful for the prevention or treatment of diseases or disorders such as HCV infection, stroke, multiple sclerosis, HBV infection, HPV infection, asthma, cancer, muscular dystrophy, sepsis, ischemia/reperfusion injury, and heart failure.